We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $214M
1-Year Est. Return 185.33%
This Fund
S&P 500
This Quarter Est. Return
+7.33%
1 Year Est. Return
+185.33%
3 Year Est. Return
+327.48%
5 Year Est. Return
+458.62%
10 Year Est. Return
+1,549.55%
AUM
$123M
AUM Growth
+$7.42M
Cap. Flow
+$6.34M
Cap. Flow %
5.16%
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
TECL icon
Direxion Daily Technology Bull 3x ETF
TECL
+$1.68M
2
PRTA icon
Prothena Corp
PRTA
+$1.5M
3
DCGO icon
DocGo
DCGO
+$960K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$794K
5
TMCI icon
Treace Medical Concepts
TMCI
+$622K

Top Sells

Rank Stock Value
1
ATEC icon
Alphatec Holdings
ATEC
+$1.12M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1M
3
ELUT icon
Elutia
ELUT
+$371K
4
PGNY icon
Progyny
PGNY
+$369K
5
CHRS icon
Coherus Oncology
CHRS
+$325K

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Energy 3.02%
3 Miscellaneous 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$1.51B
$673K 0.55%
+16,000
New +$794K
XNCR icon
27
Xencor
XNCR
$1.98B
$597K 0.49%
26,000
+13,700
+111% +$315K
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$6.08B
$593K 0.48%
30,000
– –
KALV
29
DELISTED
KalVista Pharmaceuticals
KALV
$567K 0.46%
67,000
-15,000
-18% -$155K
ATEC icon
30
Alphatec Holdings
ATEC
$1.46B
$532K 0.43%
58,000
-140,000
-71% -$1.12M
CADL icon
31
Candel Therapeutics
CADL
$978M
$521K 0.42%
+60,000
New +$355K
WVE icon
32
Wave Life Sciences
WVE
$958M
$495K 0.4%
40,000
– –
INBX icon
33
Inhibrx
INBX
$1.78B
$494K 0.4%
32,110
– –
HALO icon
34
Halozyme
HALO
$12.5B
$478K 0.39%
10,000
– –
CYTK icon
35
Cytokinetics
CYTK
$10.1B
$470K 0.38%
10,000
– –
APLS
36
DELISTED
Apellis Pharmaceuticals
APLS
$447K 0.36%
14,000
– –
SRPT icon
37
Sarepta Therapeutics
SRPT
$2.38B
$426K 0.35%
3,500
+1,000
+40% +$123K
OM icon
38
Outset Medical
OM
$67.5M
$409K 0.33%
24,584
+23,917
+3,586% +$299K
XENE icon
39
Xenon Pharmaceuticals
XENE
$5.79B
$392K 0.32%
10,000
– –
AXDX
40
DELISTED
Accelerate Diagnostics
AXDX
$390K 0.32%
325,239
– –
TELA icon
41
TELA Bio
TELA
$36.9M
$378K 0.31%
+125,000
New +$351K
SWTX
42
DELISTED
SpringWorks Therapeutics
SWTX
$361K 0.29%
10,000
– –
QURE icon
43
uniQure
QURE
$3.09B
$353K 0.29%
20,000
– –
LUNG icon
44
Pulmonx
LUNG
$94.9M
$346K 0.28%
+51,000
New +$336K
SRRK icon
45
Scholar Rock
SRRK
$6.74B
$346K 0.28%
+8,000
New +$260K
AXSM icon
46
Axsome Therapeutics
AXSM
$10.8B
$338K 0.28%
4,000
– –
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.55B
$301K 0.24%
40,000
– –
ATRA icon
48
Atara Biotherapeutics
ATRA
$98M
$293K 0.24%
+22,000
New +$232K
ARVN icon
49
Arvinas
ARVN
$614M
$288K 0.23%
15,000
– –
KPTI icon
50
Karyopharm Therapeutics
KPTI
$40.6M
$284K 0.23%
27,989
-3,333
-11% -$40.3K
1
2
3

Similar funds

EFIC
Eliot Finkel Investment Counsel Beverly Hills, California $214M AUM 62.72% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return
TCM
Tassel Capital Management Matthews, North Carolina $214M AUM 16.99% 1-Year Est. Return
EFS
Econ Financial Services Harrisburg, Pennsylvania $214M AUM 10.53% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
KWM
Kingsman Wealth Management Pensacola, Florida $214M AUM 46.9% 1-Year Est. Return
FA
Fortis Advisors Wayne, Pennsylvania $214M AUM 41.3% 1-Year Est. Return
MSWM
Mader & Shannon Wealth Management Kansas City, Missouri $214M AUM 23.75% 1-Year Est. Return

Birchview Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Birchview Capital held 71 positions worth $123M, up 6.4% from $115M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Birchview Capital deployed $6.34M of net new capital in Q4 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy and Miscellaneous.

On the sell side, the largest reduction was Alphatec Holdings, an estimated $1.12M trimmed.

  • Birchview Capital's largest Q4 2024 buy was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.
  • Birchview Capital added most to Prothena Corp in Q4 2024, an estimated $1.5M increase.
  • Birchview Capital's biggest Q4 2024 reduction was Alphatec Holdings, cutting an estimated $1.12M.
  • Birchview Capital fully exited Progyny in Q4 2024, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 65% of its $123M portfolio in Q4 2024.
  • Birchview Capital opened 10 new positions and closed 3 in Q4 2024.
  • Birchview Capital's portfolio value rose 6.4% quarter-over-quarter to $123M.

Based on Birchview Capital's 13F filing for Q4 2024, filed 14 Feb 2025.